From the Centre for Addiction and Mental Health, Toronto, ON, Canada (RAK); Department of Psychiatry, University of Toronto, Toronto, ON, Canada (RAK, MD); Department of Medicine, Dalhousie University, Halifax, NS, Canada (TDB); UCL Collaborative Centre for Inclusion Health, University College London, London, UK (TDB); Ontario Shores Centre for Mental Health Sciences, Whitby, ON, Canada (MD); Department of Psychiatry, University of Calgary, Calgary, AB, Canada (AB); British Columbia Centre on Substance Use, Vancouver, BC, Canada (AB).
Received for publication October 3, 2021; accepted November 30, 2021.
RAK, TDB, and AB received support from the Research in Addiction Medicine Scholars Program (National Institute for Drug Abuse R25DAO33211). RAK has received travel awards from the American Academy of Addiction Psychiatry and American Psychiatric Association. TDB is also supported by the Dalhousie University Internal Medicine Research Foundation Fellowship and a Canadian Institutes of Health Research Fellowship (CIHR-FRN no. 171259). AB is enrolled in the International Collaborative Addiction Medicine Research Fellowship, a US National Institute on Drug Abuse (NIDA)-funded research training fellowship offered in partnership with the BC Centre on Substance Use, St. Paul’s Hospital, and the University of British Columbia. AB is also a recipient of the 2020 Friends of Matt Newell Endowment in Substance Use from the Cumming School of Medicine at the University of Calgary and an Impact of COVID-19 on Psychiatry Grant from the American Psychiatric Association. MD reports personal fees outside of the submitted work from Otsuka, Eisai Ltd and Winterlight Labs.
The authors have no other disclosures.
Send correspondence to Robert A. Kleinman, MD, Centre for Addiction and Mental Health, Toronto, ON, Canada. E-mail: [email protected].
